US FDA Decides Against Zolgensma Data Integrity Penalties As Novartis Bureaucratizes AveXis
Company’s promise to be more forthright, along with quality culture and policy upgrades, may have helped sway agency.
Company’s promise to be more forthright, along with quality culture and policy upgrades, may have helped sway agency.